 AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we NASDAQ: ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that it has filed a provisional patent application on the use of AnPac Bios novel detection technology, methods and apparatus for coronavirus detection with the US Patent Trademark and Office on February 10, 2020, which could later lead to formal patent applications in China and other countries. AnPac Bio also announced today that it has entered into a project cooperation agreement with a hospital in China to conduct research studies on the ability of AnPac Bios CDA Cancer Differentiation Analysis technology to detect the risk of coronavirus, which is expected to be a very challenging and long term project for AnPac Bio. 